Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 1.27M | 295.39M | 330.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 1.27M | 295.39M | 330.53M |
| Cost of Revenue | 319.41M | 335.32M | 326.82M | 327.65M | 349.45M |
| Gross Profit | -319.41M | -335.32M | -325.55M | -32.26M | -18.91M |
| SG&A Expenses | 105.44M | 100.15M | 100.52M | 101.45M | 103.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 501.88M | 512.50M | 504.38M | 511.43M | 535.13M |
| Operating Income | -501.88M | -512.50M | -503.11M | -216.04M | -204.60M |
| Income Before Tax | -422.71M | -427.46M | -419.62M | -137.22M | -145.19M |
| Income Tax Expenses | 68.00K | 30.00K | 30.00K | 30.00K | 30.00K |
| Earnings from Continuing Operations | -422.77 | -427.49 | -419.65 | -137.25 | -145.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -422.77M | -427.49M | -419.65M | -137.25M | -145.22M |
| EBIT | -501.88M | -512.50M | -503.11M | -216.04M | -204.60M |
| EBITDA | -495.23M | -503.95M | -494.61M | -207.20M | -187.87M |
| EPS Basic | -2.58 | -2.76 | -2.85 | -0.93 | -1.05 |
| Normalized Basic EPS | -1.74 | -1.92 | -1.98 | -0.78 | -0.78 |
| EPS Diluted | -2.58 | -2.77 | -2.86 | -0.97 | -1.09 |
| Normalized Diluted EPS | -1.74 | -1.92 | -1.98 | -0.80 | -0.81 |
| Average Basic Shares Outstanding | 657.78M | 625.94M | 594.13M | 562.34M | 549.46M |
| Average Diluted Shares Outstanding | 657.78M | 625.94M | 594.13M | 566.22M | 553.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
